ZS portfolio and business development quarterly: Q2 2024

In our second ZS portfolio and business development quarterly webinar of the year, we reviewed the first quarter market trends shaping the pharma and biotech industry.

In this report, you’ll find insights about:

• Innovation and approvals: Small to midsize companies contributed a disproportionately high number of innovations in the first quarter, deviating from the trend of recent years.
• Funding innovation: Q1 funding remained strong compared to 2023, with venture funding seeing modest growth and IPO funding expanding significantly.
• Clinical trial trends: Trial volumes continued to decline relative to the COVID peak, as funding decreased.
• Investment activity: M&A activity is growing, and the current position is stronger than where the market started last year, but accelerated trends are needed to match 2023 end-of-year levels.

See what you need to know